4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid | 361436-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid
• CAS: 361436-69-3
• 化学式: C₁₇H₁₁FN₂O₃
• 分子量: 310.284
• InChiKey: GLKVQISUOMMOLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid 、 碘乙烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以62%的产率得到4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof

  摘要：

  该发明涉及式I的芳基取代吡啶、嘧啶、吡嗪和三嗪，或其药用可接受的盐、前药或溶剂化合物，其中A1、A2、A3、R1-R4、X和Y在规范中设定。该发明还涉及利用式I的化合物治疗全球性和局部性缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化（ALS），以及治疗、预防或改善急性或慢性疼痛，作为抗耳鸣剂，抗抽搐剂，抗躁郁症药物，局部麻醉剂，抗心律失常药物，以及治疗或预防糖尿病性神经病变。

  公开号：

  US20020040025A1
• 作为产物：
  描述：

  2-methyl-4-[4-(4-fluorophenoxy)phenyl]pyrimidine 在 sodium hydroxide 、 selenium(IV) oxide 作用下， 以 吡啶 为溶剂， 以1.5 g (80%)的产率得到4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid
  参考文献：
  名称：

  Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof

  摘要：

  该发明涉及式I的芳基取代吡啶、嘧啶、吡嗪和三嗪，或其药用可接受的盐、前药或溶剂化合物，其中A1、A2、A3、R1-R4、X和Y在规范中设定。该发明还涉及利用式I的化合物治疗全球性和局部性缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化（ALS），以及治疗、预防或改善急性或慢性疼痛，作为抗耳鸣剂，抗抽搐剂，抗躁郁症药物，局部麻醉剂，抗心律失常药物，以及治疗或预防糖尿病性神经病变。

  公开号：

  US20020040025A1

文献信息

• Aryl substituted pyrimidines
  申请人：Hogenkamp Derk J.

  公开号：US06867210B2

  公开（公告）日：2005-03-15

  This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A 1 , A 2 , A 3 , R 1 -R 4 , X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

  本发明涉及公式I中的芳基取代的吡啶、嘧啶、吡嗪和三嗪，或其药学上可接受的盐、前药或溶剂，其中A1、A2、A3、R1-R4、X和Y在规范中设置。本发明还涉及使用公式I化合物治疗全局和局部缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化（ALS），以及治疗、预防或改善急性或慢性疼痛，作为抗耳鸣剂、抗癫痫药物和抗躁狂抑郁药物，作为局部麻醉剂、抗心律失常药物以及治疗或预防糖尿病神经病变的药物。
• ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF
  申请人：Euro-Celtique S.A.

  公开号：EP1265866A2

  公开（公告）日：2002-12-18
• US6867210B2
  申请人：——

  公开号：US6867210B2

  公开（公告）日：2005-03-15
• [EN] ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF<br/>[FR] PYRIDINES, PYRIMIDINES, PYRAZINES ET TRIAZINES SUBSTITUEES PAR ARYLE ET LEUR UTILISATION
  申请人：COCENSYS INC

  公开号：WO2001068612A2

  公开（公告）日：2001-09-20

  This invention relates aryl substituted pyridines, pyrimides, pyrazines and triazines of Formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A1, A2, A3, R1-R4, X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhytmics and for the treatment of prevention of diabetic neuropathy.
• Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
  申请人：——

  公开号：US20020040025A1

  公开（公告）日：2002-04-04

  This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I: 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A 1 , A 2 , A 3 , R 1 -R 4 , X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

  该发明涉及式I的芳基取代吡啶、嘧啶、吡嗪和三嗪，或其药用可接受的盐、前药或溶剂化合物，其中A1、A2、A3、R1-R4、X和Y在规范中设定。该发明还涉及利用式I的化合物治疗全球性和局部性缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化（ALS），以及治疗、预防或改善急性或慢性疼痛，作为抗耳鸣剂，抗抽搐剂，抗躁郁症药物，局部麻醉剂，抗心律失常药物，以及治疗或预防糖尿病性神经病变。